secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001493152-23-015304
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals appoints Mark Pellegrino as CFO effective May 1, 2023
---------------------------------------------------------------------------

- Mark Pellegrino appointed CFO, replacing Robert Chen, effective May 1, 2023.
- Annual base salary of $230,000; eligible for 1.5M stock options vesting over 3 years.
- Pellegrino has 30+ years of life sciences finance experience, most recently consultant at Barbera & Barbera.
- Stock option strike price set at closing price on first day of employment (ELTP).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223015304/0001493152-23-015304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223015304/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-015304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer